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With an increasing burden of cardiovascular disease and many promising novel treatments in
development, the need for efficient systems to evaluate treatments has never been greater. To
understand whether a treatment should be used in practice, we need to know whether it
makes patients live longer, feel better, prevents adverse events, or does these things with better
tolerability or lower cost. But therapeutic development is expensive, inefficient, and is
generally focused on short-term treatment effects, rather than on prevention and on
long-term impact. Could measures of disease progression, combined with trends on clinical
outcomes and post-marketing surveillance to assess safety, serve as the foundation for
therapeutic development? Experience and principles of clinical research tell us no. Especially
in the field of heart failure, numerous treatments have appeared promising based on disease
markers, yet caused harm when tested in studies that assessed clinical outcomes. The
intersection of complex human disease, intended and unintended targets of therapy, and
overall risk and benefit make it impossible to accurately predict the effect on clinical outcomes
based on impact on a disease marker. While reliable measures of disease progression are
important to guide which treatments to study in trials, clinical outcome trials must remain the
basis for informing clinicians on which treatments improve clinical outcomes. Improved
reliability and capacity require the development of more efficient clinical trial methods,
streamlined regulatory processes, rational use of privacy protection, leveraging of electronic
medical records, and recruitment of a larger proportion of the clinical community to
participate in clinical trials. (J Am Coll Cardiol 2006;48:434–7) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.050College of Cardiology Foundation
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(Square in your ship’s path are Sirens, crying
beauty to bewitch men coasting by;
woe to the innocent who hears that sound!
Homer (1)
here has never been a greater need to enhance our ability
o determine which current and new therapies are beneficial.
ardiovascular disease will grow as the number one cause of
eath and disability worldwide (2), in part related to the
ging of the population. At the same time, especially in the
.S., the growth of health care spending is creating intense
ressure to assure that additional expenditures are worth-
hile and that quality care is being delivered. Key compo-
ents of quality involve the consistent and efficient application
f treatments that are proven to improve clinical outcomes in
safe manner (3). The medical establishment, including the
harmaceutical industry and the Food and Drug Adminis-
ration (FDA), is under increased scrutiny to foster the
evelopment of drugs and devices in a manner that provides
nformation about safety and effectiveness in general prac-
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006, accepted March 21, 2006.ice. Commonly used treatments like hormone replace-
ent therapy and cyclooxygenase-2 inhibitors have
erved to highlight the hazards of wide use of drugs for
hich safety and/or efficacy is not well established in
arge trials that include broad patient populations and
ong-term follow-up.
To decide whether a treatment is worthwhile to use,
linicians, patients, and payers need to understand the
mpact of treatment based on multiple factors—including
hether the new treatment makes patients live longer (for
atal diseases), feel better (for symptomatic diseases),
revent non-fatal clinical events (including need for
ospitalization), or do these things as well as alternatives
ut with better tolerability or lower cost (4).
The FDA has a more focused responsibility when decid-
ng whether to approve a drug. It must determine whether
drug is safe and effective. Effectiveness can be defined by
ffects on clinical outcomes, or in some cases by biologic
arkers, including blood pressure or lipid lowering. Even
hese markers, however, may only partially predict the
mpact of treatments on clinical outcome. Post-marketing
vent reporting and surveillance occasionally provide infor-
ative safety data.
In cardiovascular disease, thanks to a tradition led by
linical trials groups and countless collaborating investiga-
ors, we are fortunate to have a number of medical (5–18)
Table 1) and device treatments that have been proven to
educe mortality, most of which also improve quality of life.
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f care.
In a Viewpoint in this issue of the Journal, Cohn (19) has
utlined limitations in our current capacity to develop
herapies. We are limited in our ability to evaluate the effects
f therapies on clinical outcomes early in a disease process,
hen the risk of events is low, because we cannot predict
ong-term outcomes from short-term studies and because it
s difficult to conduct very large and long-term trials
fficiently and cost-effectively. Moreover, trials performed in
atients with most advanced disease may not be reliable
uides to the balance of benefit and risk in less severe
isease, whereas trials performed in very low-risk popula-
ions (that may also be at low risk for adverse effects) may be
nsufficiently powered to detect important treatment effects,
rom a public health perspective, that could be detected in
igher-risk cohorts.
To address these deficiencies, Cohn (19) argues that we
hould be using measures of “disease progression,” when
alid, as important determinants of treatment effect, in the
ontext of effects on quality of life and of trends on effects on
ard clinical outcomes. Thus, shorter-term, smaller trials
ould more rapidly bring promising drugs to market, and
ost-marketing surveillance could be used to further assess
afety. While appealing and critically important to guide
ecisions on which treatments are worthy of study in large
andomized trials, using measures of disease progression as
mportant information to inform treatment use has substan-
ial limitations and must be vigorously resisted.
Abbreviations and Acronyms
FDA  Food and Drug Administration
HF  heart failure
LV  left ventricular
Table 1. Medical Treatments Shown to Reduc
Trials and/or Their Overviews
Treatments (Trial Ref. #) Condition
Aspirin (5) Acute MI
Thrombolysis (6) Acute MI
Beta-blocker (7) Acute MI
ACE-I (8) Acute MI
ACE-I/ARB* (9,10) Post-MI (CHF)
Eplerenone (11) Post-MI (CHF)
Statins (12) Secondary preven
ACE-I (13) Secondary preven
Beta-blocker (14) CHF
Spironolactone (15) CHF
ACE-I/ARB† (16,17) CHF
*The VALIANT study demonstrated equivalent effect of vals
failure and/or decreased left ventricular ejection fraction; †T
the combined 2 low left ventricular ejection fraction trials. T
isosorbide dinitrate for chronic heart failure in the specific pop
and DeMets DL, Circulation 2002;106:1015–21.
ACE-I  angiotensin-converting enzyme inhibitor; AR
MI  myocardial infarction; n  to the sample size of the referen
risk reduction.It is ironic that Cohn (19) is suggesting that disease
arkers can reliably predict the impact on important clinical
utcomes, because drug development for heart failure (HF),
o which he has made major contributions, is rife with
xamples of failures of such an approach (20–30) (Table 2).
n fact, beta-blockers, not long ago, were believed to be
ontraindicated because of a negative impact on myocardial
unction, while angiotensin-converting enzyme inhibitors
ere feared to trigger atherosclerotic events in HF due to
mpaired perfusion from blood pressure lowering. Plasma
orepinephrine level, strongly related to outcome, was
elieved to be a reliable guide to impact of treatment for HF
n clinical outcomes (31,32), until moxonidine, one of the
ost potent treatments to reduce norepinephrine, was
ound to paradoxically increase mortality by 50% (27).
Why is using effect on measures of disease progression
nadequate, at least for the foreseeable future, as a method to
etermine the clinical impact of treatments?
. The complexity of human disease does not enable any
marker to be reliable enough. For most complex dis-
eases, we simply do not understand the disease well
enough to use markers of disease to predict clinical
effect. For many lifesaving treatments, including aspirin,
we have little understanding of the exact mechanism of
benefit. Inhibition of tumor necrosis factor-alpha had
supportive pre-clinical data and measurable impact on
left ventricular (LV) size and function (30), yet in trials,
the net effect appeared detrimental (29). Recently,
calcium and vitamin D were shown to significantly
improve disease progression measured by calcium con-
tent in hip bones, yet when the Women’s Health
Initiative trial was completed, they had no significant
effect on the clinical outcome of fracture (33). Thus,
using markers poses 2 hazards: treatments that affect
markers may not do so in a way that improves outcomes,
rtality in Cardiovascular Disease in Large
n RRR Absolute RR
19,302 30% 3.8%
58,000 18% 1.8%
28,970 13% 1.3%
98,496 7% 0.5%
5,966 26% 5.7%
6,632 15% 2.3%
20,536 13% 1.8%
9,297 17% 1.9%
10,480 37% 4.8%
1,663 30% 11%
2,569 16% 4.5%
ompared with captopril among patients post-MI with heart
ARM study showed reduced mortality with candesartan in
HeFT trial showed improved survival with hydralazine and
n of African Americans (18). Table adapted from Califf RM
ngiotensin receptor blocker; CHF  chronic heart failure;e Mo
tion
tion
artan c
he CH
he A
ulatio
B  a
ced trial or overview; RR  risk reduction; RRR  relative
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Measures of Disease Progression: A Sirens’ Song August 1, 2006:434–7and treatments that improve outcomes may not affect
the markers (34).
. Unintended targets are common. It is naive, in partic-
ular, given multiple examples to the contrary, to believe
that we can predict the overall impact of a treatment
based on the effect on a single measure of a disease.
Even when there are measures that accurately reflect the
impact of a treatment on disease progression—for ex-
ample, preservation of ejection fraction after fibrinolytic
therapy—these measures cannot guide treatment deci-
sions without being evaluated in the context of other
effects, such as the increase in intracranial hemorrhage.
Hormone replacement therapy has an important bene-
ficial impact on low-density lipoprotein and high-
density lipoprotein cholesterol, yet increases short-term
risk of myocardial infarction through poorly defined
mechanisms (35). Quite simply, focus on a mechanism
does not allow the essential evaluation of the balance
between benefit and risk.
. Assessing disease progression in fatal disease is con-
founded, including by “survival bias.” Because a basic
condition of validity of the randomized clinical trial
depends on assessing (nearly) all randomized patients to
assure balance of unmeasured confounders, use of an
outcome that depends on acquisition and survival pre-
sents a methodologic challenge. For example, use of
improvement in LV ejection fraction as a measure of
benefit from fibrinolytic therapy was limited by the fact
that more sick patients in the control group died, so that
surviving patients with lower ejection fraction in the
fibrinolytic therapy group masked the beneficial effect (36).
. Integration of safety, efficacy, and cost-effectiveness is
not possible based on assessment of markers of disease
progression. More and more, we need to know not only
if a treatment is effective, but how effective and the net
magnitude of effect given the cost. Thus, not only are
large trials needed with adequate numbers of clinical
end points to assess risk and benefit in an integrated
fashion, but the trials should be done in populations that
represent where the treatment is intended to be used.
If studying the impact of treatments on disease progres-
able 2. Selected Trials of Treatments With Divergent Effects o
yocardial Infarction and/or With HF
Trials (Ref. #) Treatments
Im
AST (20) Flecainide and encainide Fewe
ROMISE (21) Milrinone Impr
ROFILE (23) Flosequinan Impr
esnarinone trial (25) Vesnarinone Impr
OXCON (27) Moxonidine Redu
ENEWAL (29) Etanercept Dose
fra
AST  Cardiac Arrhythmia Supression Trial; HF  heart failure; LV  left ven
ustained-Release Moxonidine in Patients with Heart Failure study; PROFILE  E
ral Milrinone on Mortality in Severe Chronic Heart Failure study; RENEWAL ion will not provide the solution to the challenges Cohn C19) outlines, what will? It is true that exclusive focus on
ll-cause mortality will prevent insights that can help refine
ffective treatments by understanding the balance of bene-
cial and harmful effects and best dosing. Because 1 in 10
rugs tested in humans will ever come to market, smarter
hoices based on better markers of disease progression are
eeded to guide which treatments to study in large (and
xpensive) trials. As we contemplate the era of genomic
edicine, a refined ability to decide which treatments to test
n which patients based on details of disease manifestation
ill be especially important. We agree with Cohn (19) that
ertain measures, including impact of HF treatments of
entricular volume, may both correlate with clinical out-
omes and reflect a major pathway by which certain treat-
ents translate into improved clinical outcomes, and such
easures may be very important in helping to decide which
reatments will be likely to improve survival and quality
f life.
Most importantly, we need improved methods to effi-
iently test the impact of promising therapies on clinical
utcomes. This requires the development of more efficient
linical trial methods, streamlined regulatory processes,
ational use of privacy protection, leveraging of electronic
edical records, recruitment of a larger proportion of the
linical community to participate in clinical trials, and integra-
ion of trials with registries to assess the use and safety of
reatments in observational studies. Efficient conduct of trials
n developing health care systems and focus of the National
nstitutes of Health on re-engineering the U.S. clinical re-
earch enterprise (37) offer important opportunities.
Ultimately, both improved ability to predict which treat-
ents will be effective by better ability to measure disease
rogression and more efficient, long-term, real-world clin-
cal trials are needed. For the time being, large, long-term
linical trials must serve as the standard for determining risk
nd benefit to establish which treatments improve cardio-
ascular health.
eprint requests and correspondence: Dr. Christopher B. Granger,
uke Clinical Research Institute, Duke University Medical Center,
400 Pratt Street, Room 0311 Terrace Level, Durham, North
ease Markers and Clinical Outcomes of Patients After
on Disease Measure and/or
hort-Term Symptoms Impact on Clinical Outcome
ature ventricular contractions Higher mortality
hemodynamics (22) Higher mortality
exercise time (24) Higher mortality
short-term quality of life (26) Higher mortality
in plasma norepinephrine (28) Higher mortality
ndent improvement in ejection
and LV remodeling (30)
No reduction in death or
HF hospitalizations
r; MOXCON  Adverse Mortality Effect of Central Sympathetic Inhibition with
f Flosequinan on Survival in Chronic Heart Failure study; PROMISE  Effect of
domized Etanercept Worldwide Evaluation study.n Dis
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